Ru Xin Wong, Radiation Oncologist at Proton Therapy SG, shared a post on LinkedIn:
“Helped judge and moderate some sessions at PTCOG Asia 2025 in Hong Kong.
It was inspiring to see how particle therapy continues to evolve across Asia — with growing evidence for newer indications such as cervical cancers, unresectable adenoid cystic carcinoma, and stage III lung cancers.
Equally exciting is the increasing integration of AI in clinical workflows, helping to make treatment more precise, efficient, and less burdensome for patients.
The future of particle therapy in Asia looks bright.“
More posts featuring Ru Xin Wong.
